Drug intelligence / Profile preview

let-7 mimic

Development stage
Preclinical
Lead developer
Synlogic
Modality
RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intratumoral
01

Overview

A let-7 mimic is a synthetic double-stranded RNA oligonucleotide designed to replicate the biological activity of the endogenous tumor suppressor microRNA, let-7. The let-7 family is one of the most well-studied microRNA groups and is frequently downregulated in various malignancies, including lung, ovarian, and breast cancers. By mimicking the natural let-7 microRNA, these synthetic agents bind to the 3' untranslated regions (UTRs) of specific oncogenic mRNAs, such as RAS, MYC, HMGA2, and Cyclin D1, leading to their degradation or translational repression. This restoration of let-7 activity aims to inhibit tumor cell proliferation, induce apoptosis, and overcome resistance to conventional therapies like platinum-based chemotherapy. Development of let-7 mimics as therapeutics often involves advanced delivery systems, such as lipid nanoparticles, to protect the RNA from nuclease degradation and facilitate targeted delivery to tumor tissues.

Other names
let-7 microRNA mimiclet7 microRNA mimiclet 7 microRNA mimiclet-7 miRNA mimiclet7 miRNA mimiclet 7 miRNA mimicsynthetic let-7
02

Targets

CCND1 (Cyclin D1)HMGA2 (High mobility group AT-hook 2)MYC (MYC proto-oncogene protein)Kirsten rat sarcoma viral oncogene homolog mRNA

Beyond the preview

Go deeper on let-7 mimic.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on let-7 mimic.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call